|
**Overview**: **IMD Quantitative Profile****Introduction**: The IMD Quantitative Profile is a diagnostic tool designed to screen for inborn metabolic disorders using whole blood samples. Associated with conditions like phenylketonuria and maple syrup urine disease, these disorders present with developmental delay, odor changes, and severe complications if untreated, particularly in individuals with suspected metabolic issues. Per the 2023 Biochemistry guidelines, the test employs biochemistry with HPLC-MS/MS technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for metabolic screening in clinical settings. This diagnostic falls under metabolic screening and targets individuals with suspected inborn metabolic disorders, addressing the challenge of accurate metabolite assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: IMD Quant Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by metabolic labs, this test advanced inborn error diagnostics.**Purpose**: The test screens for 39 parameters including alanine to guide metabolic assessment, assess amino acids and carnitine profiles, and inform treatment and prevention strategies.**Test Parameters**: 1. Alanine, 2. Arginine, 3. Citrulline, 4. Glycine, 5. Leucine, 6. Methionine, 7. Phenylalanine, 8. Tyrosine, 9. Valine, 10. Ornithine, 11. Proline, 12. Glutamine, 13. Histidine, 14. Lysine, 15. Asparagine, 16. Serine, 17. Threonine, 18. Tryptophan, 19. C0 (Free Carnitine), 20. C2 (Acetylcarnitine), 21. C3 (Propionylcarnitine), 22. C4 (Butyrylcarnitine), 23. C5 (Isovalerylcarnitine), 24. C6 (Hexanoylcarnitine), 25. C8 (Octanoylcarnitine), 26. C10 (Decanoylcarnitine), 27. C12 (Lauroylcarnitine), 28. C14 (Myristoylcarnitine), 29. C16 (Palmitoylcarnitine), 30. C18 (Stearoylcarnitine), 31. Succinylacetone, 32. Methylmalonic Acid, 33. Homocysteine, 34. 3-Hydroxybutyric Acid, 35. Acetoacetic Acid, 36. Lactic Acid, 37. Pyruvic Acid, 38. Glutaric Acid, 39. 3-Hydroxyglutaric Acid.**Pretest Condition**: No fasting required; patients should report developmental delay, odor changes, or recent metabolic symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve analyte integrity.**Medical History**: Patients should provide details on developmental delay, odor changes, prior metabolic reactions, or family history of inborn errors, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated metabolic disorders including brain damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using HPLC-MS/MS and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent dietary changes can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible inborn metabolic disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in metabolic disorders should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Urine organic acid analysis or enzyme assays for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry Guidelines 2023, Journal of Metabolic Diseases 2024, Chemistry 2025. |
